Jun 01,2023

Dario Management to Participate in the Stifel 2023 Virtual Cross Sector Insight Conference

DarioHealth, a leader in the global digital health market, announced today that the Company will participate in the Stifel 2023 Virtual Cross Sector Insight Conference, which is being held June 6-7, 2023, at The Intercontinental in Boston, MA. Rick Anderson, President of Dario, is scheduled to give a company presentation on Tuesday, June 6, 2023, at 4:45 PM EST.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Jun 01,2023

Glucose Monitoring Devices Market Size to Hit US$ 23.19 Billion by 2031

According to a market analysis conducted by Growth Plus Reports, the global glucose monitoring devices market was valued at US$12.72 billion in 2022. It is projected to experience a revenue compound annual growth rate (CAGR) of 7.8% and reach US$23.19 billion by 2031. The market is driven by factors such as the increasing incidence of diabetes and the demand for reliable and user-friendly glucose monitoring solutions, presenting lucrative opportunities for industry players.

#bgm

#cgm

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Jun 02,2023 TOP STORY

Senseonics Announces UnitedHealthcare Coverage of Eversense® E3 CGM for Adults with Diabetes

Senseonics, a medical technology company, announced that UnitedHealthcare, the largest health insurance company in the US, will provide coverage for the Eversense E3 CGM System starting July 1, 2023 for people with type 1 and insulin-requiring type 2 diabetes. This milestone expands access to over 45 million lives covered by UnitedHealthcare, benefiting people with type 1 and insulin-requiring type 2 diabetes. With this collaboration and extensive coverage, the Eversense CGM System can now reach approximately 300 million covered lives, enhancing diabetes management and improving patient care.

COLLABORATION PARTNERSHIP

#insurance

#cgm

View Analyst & Ambassador Comments
Go to original news
May 30,2023

FDA green-lights bionic pancreas studied at UT Health Science Center San Antonio, University Health

The University of Texas Health Science Center at San Antonio and its clinical partner, University Health, have received FDA clearance for the "bionic pancreas," an AI-powered system that helps manage insulin delivery for children with type 1 diabetes. The system, paired with a continuous glucose monitoring system, relieves parents and children of the constant stress of estimating insulin doses and carbohydrate intake. The device, about the size of a cell phone, uses AI algorithms to learn the patient's insulin requirements, providing a simpler and more automated approach to diabetes management.

REGULATORY FDA

#closed loop

#cgm

View Analyst & Ambassador Comments
Go to original news
May 30,2023

Lilly to Participate in Goldman Sachs Global Healthcare Conference

Eli Lilly and Company will participate in the Goldman Sachs 44th Annual Global Healthcare Conference on June 12-13, 2023. Anat Ashkenazi, Lilly's executive vice president and chief financial officer, will engage in a fireside chat during the event. A live audio webcast will be available on Lilly's Investor website, and a replay will be accessible for approximately 90 days. Lilly aims to create medicines that improve the lives of people worldwide and is dedicated to advancing healthcare discoveries.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
May 31,2023

A Global Glucose Monitoring Market Report Predicts $33 Billion Market Size by 2029

The global glucose monitoring market is expected to reach $33,886.4 million by 2029, growing at a double-digit CAGR from 2022, according to the publisher. Key drivers include the global rise in diabetes prevalence, demand for minimally invasive devices, and increasing R&D investments. Major players in the market include Abbott Laboratories, Dexcom, Roche, and Medtronic. Invasive glucose monitoring products, particularly continuous glucose monitoring, accounted for the largest share in 2022. North America leads the market, while Europe and Asia-Pacific are projected to grow significantly.

View Analyst & Ambassador Comments
Go to original news
May 24,2023

Omada Health Launches GLP-1-Specific Program for Patients Battling Chronic Obesity

Omada Health, a virtual healthcare provider, has introduced a specialized program for individuals taking GLP-1 medications to address chronic obesity. The program combines behavior and lifestyle changes with medication to support sustained weight loss. Omada's program includes training for health coaches, educational resources for members, a peer support group, and infrastructure support for employers and PBMs to administer coverage policies. The program aims to maximize the benefits of GLP-1 medications and promote long-term weight management.

PRODUCT

#coaching

#dtx

View Analyst & Ambassador Comments
Go to original news
May 25,2023

Vietnam Pediatric Association and Roche pledge to enhance access to care for children with Type 1 diabetes under the Changing Diabetes® in Children programme

Roche Diabetes Care and The Vietnam Pediatric Association have joined forces under the Changing Diabetes® in Children program to improve access to care for underprivileged children with Type 1 diabetes in Vietnam. The partnership aims to provide diabetes monitoring and management kits to all 2,600 children with Type 1 diabetes in Vietnam, along with education and training for healthcare professionals and increased awareness among patients and their families. This collaboration is part of a global initiative led by Novo Nordisk and Roche to broaden access to care for children with diabetes worldwide.

COLLABORATION PARTNERSHIP

#institution

#bgm

View Analyst & Ambassador Comments
Go to original news
May 25,2023

Medtronic to acquire wearable insulin patch maker EOFlow for $738M

Medtronic, a leading medical technology company, has announced its acquisition of EOFlow, a wearable insulin patch maker, for $738 million. EOFlow's flagship product, the EOPatch, is a tubeless, disposable insulin delivery device that has already been launched in Korea and Europe. EOFlow has also obtained FDA breakthrough device designation for its wearable artificial pancreas. Medtronic plans to integrate EOFlow's offerings, including its glucose monitoring sensor and insulin pump, into its existing diabetes portfolio, which recently received FDA approval for the MiniMed 780G, a closed-loop artificial pancreas.

COLLABORATION MERGERS & ACQUISITION

#product & service

#insulin pump

#closed loop

View Analyst & Ambassador Comments
Go to original news
May 26,2023

Senseonics to Participate in the Jefferies Healthcare Conference

Senseonics Holdings, a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming Jefferies Healthcare Conference in New York, NY. Management is scheduled to present on Friday, June 9, 2023, from 9:30am to 9:55am ET.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES